



CHEPLAPHARM ENGAGED DKSH TO MARKET ITS REGIONAL BUSINESS IN SEVERAL ASIAN COUNTRIES

Zurich (CH) / Greifswald (DE), December 15, 2017 – In a formal ceremony at the DKSH headquarters in Zurich, DKSH and CHEPLAPHARM Arzneimittel GmbH have signed a strategic partnership for a regional cooperation in several countries in Asia.

With its latest acquisitions, CHEPLAPHARM has recently further extended and diversified its product portfolio. DKSH has now been appointed to actively manage and promote CHEPLAPHARM's branded products in selected markets in Asia, for example in Thailand, Malaysia, Singapore, Myanmar, Cambodia, Hong Kong and Macau. Besides serving the patients' needs in these markets, it is also the target of this cooperation to boost the company's presence within this important region.

DKSH is the leading Market Expansion Services Group with a focus on Asia, supporting companies to grow their business in new or existing markets. Their dedicated team of experts provides a broad spectrum of integrated Market Expansion Services across the entire value chain. In order to realize and further develop our ambitious growth strategy and to benefit from DKSH's in-depth knowledge of the local markets and their well-established distribution network across Asia which allows them to provide regional solutions by duplicating success across markets, CHEPLAPHARM has stepped into this strategic collaboration.

CHEPLAPHARM's Management Board: „We are very impressed by and highly value DKSH's experience and expertise in Asia and are looking forward to mutually develop and foster a close, trustful and professional partnership with our new business partners.“

„We have come to know CHEPLAPHARM as a company with great potential. With the largest dedicated salesforce in Asia and an unwavering commitment to quality and compliance, we are keen to drive sales for our new partner CHEPLAPHARM,“ said Bijay Singh, Head, Business Unit Healthcare, DKSH.

About DKSH

DKSH is the leading Market Expansion Services provider with a focus on Asia. As the term "Market Expansion Services" suggests, DKSH helps other companies and brands to grow their business in new or existing markets. Publicly listed on the SIX Swiss Exchange since 2012, DKSH is a global company headquartered in Zurich. With 780 business locations in 36 countries – 750 of them in Asia – and 30,320 specialized staff, DKSH generated net sales of CHF 10.5 billion in 2016. DKSH was founded in 1865. With strong Swiss heritage, the company has a long tradition of doing business in and with Asia and is deeply rooted in communities and businesses across Asia Pacific.

Further information about DKSH can be found at www.dksh.com.

About CHEPLAPHARM

CHEPLAPHARM is a family owned pharmaceutical company with its headquarters situated in Germany and offering branded products on a global level.

The company focuses on an internationally oriented Buy and Build Strategy. In close collaboration with its business partners, CHEPLAPHARM generates sustainable annual growth rates.

CHEPLAPHARM specializes in selected active substances and indications and commits itself to provide branded products of high quality and to guarantee continuous availability to its costumers. Please refer to www.cheplapharm.com for additional information.

Press office:

CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | [presse\(at\)cheplapharm.com](mailto:presse(at)cheplapharm.com)